Daniel Lee, Mary Slomkowski, Nanco Hefting, Dalei Chen, Klaus Groes Larsen, Eva Kohegyi, Mary Hobart, Jeffrey L Cummings, George T Grossberg
IMPORTANCE: Agitation is a prevalent, distressing, and burdensome manifestation of Alzheimer dementia in need of an efficacious, safe, and well-tolerated treatment. OBJECTIVE: To confirm the efficacy, safety, and tolerability of brexpiprazole in patients with agitation in Alzheimer dementia. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was a 12-week, double-blind, placebo-controlled, fixed-dose, parallel-arm trial that ran from May 2018 to June 2022 at 123 clinical trial sites in Europe and the United States...
November 6, 2023: JAMA Neurology